BridgeBio Pharma Inc.
Returns on Capital
| Period | ROE | ROI | ROA |
|---|---|---|---|
| Sep 2018 | -25.4% | -25.4% | — |
| Mar 2019 | -27.5% | -27.5% | — |
| Jun 2019 | -45.6% | -45.6% | — |
| Sep 2019 | -13.2% | -11.3% | -9.5% |
| Mar 2020 | -27.3% | -22.0% | -10.5% |
| Jun 2020 | -51.3% | -38.0% | -15.0% |
| Sep 2020 | -79.5% | -50.6% | -16.5% |
| Mar 2021 | 43.3% | 56.2% | -15.6% |
| Jun 2021 | 22.0% | 28.2% | -9.4% |
| Sep 2021 | 21.7% | 25.1% | -20.6% |
| Mar 2022 | 19.3% | 33.2% | -24.8% |
| Jun 2022 | 0.2% | 0.2% | -0.3% |
| Sep 2022 | 12.3% | 12.3% | -19.2% |
| Mar 2023 | 11.6% | 18.1% | -22.8% |
| Jun 2023 | 11.8% | 17.4% | -31.9% |
| Sep 2023 | 14.9% | 23.4% | -27.4% |
| Mar 2024 | 3.4% | 5.9% | -4.3% |
| Jun 2024 | 6.9% | 11.5% | -9.5% |
| Sep 2024 | 13.4% | 20.7% | -24.7% |
| Mar 2025 | 10.3% | 10.3% | -19.2% |
| Jun 2025 | 10.3% | 10.3% | -17.0% |
| Sep 2025 | 9.6% | -249.0% | -18.5% |
| Mar 2026 | 7.3% | -44.5% | -12.1% |
| Jun 2026 | 6.2% | -113.2% | -12.8% |